Teva announces launch of first generic version of azopt® (brinzolamide ophthalmic suspension) 1%, used to treat high pressure inside the eye, in the united states

Tel aviv & parsippany, n.j.--(business wire)--teva pharmaceuticals usa, inc., a u.s. affiliate of teva pharmaceutical industries ltd.(nyse and tase: teva), today announced its launch of the first available generic version of azopt® (brinzolamide ophthalmic suspension) 1%, approved by the us food and drug administration to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma. brinzolamide ophthalmic suspension 1% works by decreasing the amount of fluid within the
TEVA Ratings Summary
TEVA Quant Ranking